Question 1

What Is GLP-3 Reta? GLP-1/GIP/Glucagon Tri-Agonist Research Peptide

Accepted Answer

GLP-3 Reta is a synthetic tri-agonist peptide developed by Eli Lilly, designated LY3437943 in clinical trial documentation. It simultaneously targets three receptor types: GLP-1, GIP, and glucagon receptors. That triple-receptor profile distinguishes it from earlier incretin-based research compounds and has made it one of the more closely followed investigational peptides in the metabolic research literature.

Question 2

Mechanism: Three Receptors, One Molecule

Accepted Answer

GLP-1 receptor agonism is the foundation. GLP-1 Sema established GLP-1 as a viable research target, and GLP-3 Reta builds on that by adding two more receptor interactions. GIP receptor co-agonism was first documented as clinically meaningful through GLP-2 Tirz's Phase 3 data. GLP-3 Reta adds glucagon receptor activity as a third element. Glucagon receptor agonism is the differentiator here. Glucagon signals the liver to release stored glucose and also appears to increase energy expenditure in animal models by activating brown adipose tissue thermogenesis. Adding this receptor to the GLP-1/GIP profile creates a compound with a distinct mechanistic signature compared to either GLP-1 Sema or GLP-2 Tirz.

Question 3

Documented Research History

Accepted Answer

Phase 1 studies of GLP-3 Reta established pharmacokinetic parameters and initial tolerability data. Phase 2 results, published in the New England Journal of Medicine in July 2023 by Jastreboff and colleagues, reported body weight change data at multiple dose levels over 48 weeks. The highest-dose cohort showed the largest reductions in the primary endpoint. Phase 3 trials, branded TRIUMPH by Lilly, were initiated in late 2023. These trials are enrolling larger populations with longer follow-up periods to establish the evidence package needed for regulatory review. No approval timeline has been officially announced.

Question 4

Research Compound Classification

Accepted Answer

GLP-3 Reta is classified as an investigational drug in clinical trial contexts and as a research peptide for in vitro laboratory use. It's not a pharmaceutical product available through licensed prescribers. Spartan Peptides supplies GLP-3 Reta as a lyophilized research compound, verified by HPLC and mass spectrometry, for laboratory research applications only.

Question 5

How Researchers Are Studying It

Accepted Answer

In vitro studies have examined GLP-3 Reta's receptor binding kinetics and downstream signaling in cell lines expressing individual and combined receptor types. Published mechanistic work complements the clinical data and helps researchers understand which aspects of the compound's activity are receptor-mediated versus off-target effects. The compound's once-weekly half-life also distinguishes it from shorter-acting research peptides, which has implications for in vivo model design in terms of dosing interval and steady-state concentration calculations.

GLP-3(Reta) | Triple-Agonist Metabolic Research

NAD+ 750mg | Cellular Energy & DNA Repair Research

MOTS-c | Mitochondrial Metabolism Research Peptide

BPC-157 5mg | Tissue Repair & Gut Health Research

What Is GLP-3 Reta? Frequently Asked Questions

Explore Full Research Index